AP851A - Composition comprising amoxycillin and clavulanic acid. - Google Patents

Composition comprising amoxycillin and clavulanic acid. Download PDF

Info

Publication number
AP851A
AP851A APAP/P/1997/001122A AP9701122A AP851A AP 851 A AP851 A AP 851A AP 9701122 A AP9701122 A AP 9701122A AP 851 A AP851 A AP 851A
Authority
AP
ARIPO
Prior art keywords
amoxycillin
formulation
day
clavulanic acid
acid
Prior art date
Application number
APAP/P/1997/001122A
Other languages
English (en)
Other versions
AP9701122A0 (en
Inventor
Richard Peregrine Bax
Mike Gale Ramsey
Original Assignee
Smithkline Beecham Plc
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26306975&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP851(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9508989.2A external-priority patent/GB9508989D0/en
Priority claimed from GBGB9523655.0A external-priority patent/GB9523655D0/en
Application filed by Smithkline Beecham Plc, Smithkline Beecham Corp filed Critical Smithkline Beecham Plc
Publication of AP9701122A0 publication Critical patent/AP9701122A0/xx
Application granted granted Critical
Publication of AP851A publication Critical patent/AP851A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
APAP/P/1997/001122A 1995-05-03 1996-05-02 Composition comprising amoxycillin and clavulanic acid. AP851A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9508989.2A GB9508989D0 (en) 1995-05-03 1995-05-03 Pharmaceutical formulations
GBGB9523655.0A GB9523655D0 (en) 1995-11-18 1995-11-18 Method of treatment
PCT/EP1996/001881 WO1996034605A1 (en) 1995-05-03 1996-05-02 Composition comprising amoxycillin and clavulanic acid

Publications (2)

Publication Number Publication Date
AP9701122A0 AP9701122A0 (en) 1997-10-31
AP851A true AP851A (en) 2000-06-15

Family

ID=26306975

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1997/001122A AP851A (en) 1995-05-03 1996-05-02 Composition comprising amoxycillin and clavulanic acid.

Country Status (33)

Country Link
EP (2) EP0825860B1 (ro)
JP (1) JP3480939B2 (ro)
KR (2) KR20050084498A (ro)
CN (1) CN1104240C (ro)
AP (1) AP851A (ro)
AR (1) AR002993A1 (ro)
AT (2) ATE206051T1 (ro)
AU (1) AU712269C (ro)
BG (2) BG64270B1 (ro)
BR (1) BR9608270A (ro)
CZ (1) CZ294434B6 (ro)
DE (1) DE69615551T2 (ro)
DK (1) DK0825860T3 (ro)
DZ (1) DZ2028A1 (ro)
EA (1) EA001878B1 (ro)
ES (1) ES2160821T3 (ro)
GR (1) GR3036722T3 (ro)
HK (1) HK1009101A1 (ro)
HU (2) HUP9801064A3 (ro)
IL (1) IL118091A (ro)
MA (1) MA24339A1 (ro)
MY (1) MY127622A (ro)
NO (1) NO975037L (ro)
NZ (1) NZ308478A (ro)
OA (1) OA10533A (ro)
PE (1) PE20011100A1 (ro)
PL (1) PL323103A1 (ro)
PT (1) PT825860E (ro)
RO (1) RO116343B1 (ro)
SK (1) SK283794B6 (ro)
TR (1) TR199701294T1 (ro)
UA (1) UA46763C2 (ro)
WO (1) WO1996034605A1 (ro)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL123563A (en) 1995-09-07 2002-02-10 Smithkline Beecham Corp Pharmaceutical formulations comprising amoxycillin and clavulanate in a weight ratio between 14:1 and 16:1 inclusive
GB9617780D0 (en) * 1996-08-24 1996-10-02 Smithkline Beecham Plc Method of treatment
GB9815532D0 (en) 1998-07-17 1998-09-16 Lek Pharmaceutical & Cvhemical Pharmaceutical suspension formulation
US6177421B1 (en) 1999-05-04 2001-01-23 Fuisz International Ltd. Amoxicillin and clavulanate composition
IE990159A1 (en) * 1999-02-26 2000-09-20 Fuisz Internat Ltd Storage Stable Amoxycillin and Clavulanate Suspension Composition.
US7250176B1 (en) 1999-04-13 2007-07-31 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection
US6294199B1 (en) 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin
US6878386B1 (en) 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
US6156294A (en) * 1999-11-28 2000-12-05 Scientific Development And Research, Inc. Composition and method for treatment of otitis media
US6756057B2 (en) 2000-10-12 2004-06-29 Beecham Pharmaceuticals (Pte) Limited Amoxicillin and potassium clavulanate dosage form
AU2001292185A1 (en) 2000-10-12 2002-04-22 Beecham Pharmaceuticals (Pte) Limited Formulation containing amoxicillin
CN100391456C (zh) * 2005-04-30 2008-06-04 南京师范大学 β-环糊精/阿莫西林包合物及其与克拉维酸钾的组合物及制备方法
DE102006007830A1 (de) * 2006-02-17 2007-08-30 Grünenthal GmbH Lagerstabile orale Darreichungsform von Amoxicillin und Clavulansäure
CN101406450B (zh) * 2007-10-12 2010-08-25 河南农业大学 复方阿莫西林油混悬注射液制备工艺
MX2014008375A (es) * 2012-01-10 2017-07-27 Spector Michael Formulaciones pedriaticas de supspension oral de amoxicilina y clauvulanato de potasio y metodo para su uso.
WO2013173808A2 (en) * 2012-05-17 2013-11-21 Michael Spector Methods for use of lower dose compositions of amoxicillin and clavulanate potassium and devices for use
WO2013173803A2 (en) * 2012-05-17 2013-11-21 Michael Spector Formulations of amoxicillin and clavulanate potassium and methods for using same
CN106474122B (zh) * 2016-09-07 2020-04-14 湘北威尔曼制药股份有限公司 一种阿莫西林克拉维酸钾的药物组合物及其应用
CN108403676B (zh) * 2018-03-20 2020-08-21 中山大学 琥珀酸在提高细菌对抗生素敏感性方面的应用
CN116327760A (zh) * 2022-12-26 2023-06-27 南京臣功制药股份有限公司 一种阿莫西林克拉维酸钾缓释干混悬剂及其制备方法
CN117379378A (zh) * 2023-12-07 2024-01-12 山东金瑞生物科技有限公司 一种兽用复方阿莫西林可溶性粉及其制备工艺

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO984B1 (en) * 1977-10-11 1979-12-01 بيتشام غروب ليمتد A dry pharmaceutical compound with a suitable dosage unit for oral administration
US4337887A (en) 1979-09-18 1982-07-06 Weyerhaeuser Company Reinforced half slotted container
NZ198241A (en) * 1980-09-27 1983-12-16 Beecham Group Ltd Tablet containing amoxycillin and potassium clavulanate
DE3266580D1 (en) * 1981-12-02 1985-10-31 Beecham Group Plc Pharmaceutical formulation comprising beta-lactam antibiotics
GB9007945D0 (en) * 1990-04-07 1990-06-06 Beecham Group Plc Pharmaceutical formulation
GB9408117D0 (en) * 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
GB9416599D0 (en) 1994-08-17 1994-10-12 Smithkline Beecham Plc Pharmaceutical formulation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CAN.MED.ASSOC.J., vol. 142, no. 2, 15 January 1990, pages 115-118 *
J.INT.MED.RES., vol. 17, no. 2, 1989, pages 168-171 *

Also Published As

Publication number Publication date
BG64270B1 (bg) 2004-08-31
SK146297A3 (en) 1998-05-06
CZ294434B6 (cs) 2005-01-12
MY127622A (en) 2006-12-29
EP0825860B1 (en) 2001-09-26
BG64271B1 (bg) 2004-08-31
HUP9801064A3 (en) 1998-11-30
RO116343B1 (ro) 2001-01-30
AR002993A1 (es) 1998-05-27
CN1189100A (zh) 1998-07-29
EA001878B1 (ru) 2001-10-22
JPH11504911A (ja) 1999-05-11
ATE206051T1 (de) 2001-10-15
NO975037D0 (no) 1997-10-31
PT825860E (pt) 2002-01-30
DK0825860T3 (da) 2001-11-19
EP0825860A1 (en) 1998-03-04
PE20011100A1 (es) 2002-01-06
EP1013274A3 (en) 2000-07-05
MA24339A1 (fr) 1998-07-01
BR9608270A (pt) 1999-05-04
DE69615551T2 (de) 2002-04-25
JP3480939B2 (ja) 2003-12-22
TR199701294T1 (xx) 1998-04-21
AT4423U1 (de) 2001-07-25
AP9701122A0 (en) 1997-10-31
NO975037L (no) 1997-10-31
KR20050084498A (ko) 2005-08-26
AU5814096A (en) 1996-11-21
OA10533A (en) 2002-04-29
IL118091A0 (en) 1996-09-12
PL323103A1 (en) 1998-03-16
DZ2028A1 (fr) 2002-10-23
BG102024A (en) 1998-07-31
UA46763C2 (uk) 2002-06-17
ES2160821T3 (es) 2001-11-16
CZ345997A3 (cs) 1998-03-18
CN1104240C (zh) 2003-04-02
GR3036722T3 (en) 2001-12-31
BG106763A (en) 2004-05-31
EA199700354A1 (ru) 1998-04-30
IL118091A (en) 2004-07-25
NZ308478A (en) 1999-04-29
SK283794B6 (sk) 2004-01-08
WO1996034605A1 (en) 1996-11-07
EP1013274A2 (en) 2000-06-28
KR19990008253A (ko) 1999-01-25
DE69615551D1 (de) 2001-10-31
HK1009101A1 (en) 1999-05-28
AU712269B2 (en) 1999-11-04
AU712269C (en) 2002-06-06
HU0201920D0 (ro) 2002-08-28
HUP9801064A2 (hu) 1998-08-28

Similar Documents

Publication Publication Date Title
AP851A (en) Composition comprising amoxycillin and clavulanic acid.
AU722657B2 (en) Use of a combination of amoxycillin and clavulanate in the manufacture of a medicament for the treatment drug-resistant streptococcus pneumonia
EP0862431B1 (en) Use of a paediatric pharmaceutical formulation comprising amoxycillin and clavulanate
AU762840B2 (en) Pharmaceutical suspension formulation comprising amoxycillin, clavulanic acid and cellulose
US20020099044A1 (en) Composition comprising amoxycillin and clavulanic acid
ZA200510098B (en) Pharmaceutical formulations comprising amoxicillin and clavulanate
CA2220103C (en) Composition comprising amoxycillin and clavulanic acid
EP1491195A1 (en) Pharmaceutical formulations comprising amoxicillin and clavulanate
CZ11407U1 (cs) Farmaceutický prostředek uzpůsobený pro pediatrické podávání
MXPA99001807A (en) Use of a combination of amoxycillin and clavulanate in the manufacture of a medicament for the treatment drug-resistant streptococcus pneumonia
MXPA98001903A (en) Farmaceut formulation